gp100 (71-78)

gp100 (71-78) is a synthetic peptide fragment corresponding to amino acids 71 through 78 of the human glycoprotein 100, a melanocyte differentiation antigen also known as premelanosome protein (PMEL or gp100). As a defined peptide epitope, it is widely recognized for its role in immunological studies, particularly those investigating antigen processing, presentation, and T cell recognition associated with melanoma research. The sequence specificity and molecular fidelity of gp100 (71-78) make it a valuable tool for dissecting peptide-MHC interactions, evaluating immune responses, and supporting the development of experimental immunotherapeutic strategies in preclinical settings.

Epitope mapping: In immunology research, gp100 (71-78) serves as a critical reagent for mapping T cell epitopes and characterizing antigen-specific T lymphocyte responses. Its defined sequence enables precise evaluation of peptide binding to major histocompatibility complex (MHC) molecules, facilitating studies on T cell receptor (TCR) specificity and the mechanisms governing immune recognition of melanoma-associated antigens. These insights are essential for understanding the molecular basis of antigenicity and immune surveillance in cancer biology.

Antigen presentation studies: The peptide is routinely employed in assays designed to investigate the processing and presentation of tumor antigens by antigen-presenting cells (APCs). By pulsing dendritic cells or other APCs with gp100 (71-78), researchers can assess the efficiency of peptide loading, MHC class I presentation, and subsequent activation of cytotoxic T lymphocytes (CTLs). Such experimental approaches are fundamental to elucidating how tumor-derived peptides are presented to the immune system and how immune evasion may occur in malignant contexts.

T cell activation assays: gp100 (71-78) is frequently utilized in in vitro T cell activation assays to stimulate antigen-specific CD8+ T cells. By incorporating the peptide into co-culture systems, investigators can quantify T cell proliferation, cytokine production, and cytolytic activity, providing a functional readout of immune competence and specificity. These applications are particularly relevant for evaluating T cell responses in animal models or human samples exposed to melanoma antigens.

Peptide-based vaccine research: The defined nature of gp100 (71-78) supports its use in the development and evaluation of experimental peptide-based vaccine platforms targeting melanoma antigens. The peptide can be formulated with adjuvants or delivery systems to assess immunogenicity, optimize antigen presentation, and enhance the induction of antigen-specific T cell responses in preclinical models. These studies contribute foundational knowledge for the rational design of next-generation immunotherapeutic strategies.

Analytical assay development: In addition to its immunological applications, gp100 (71-78) is also used as a reference standard or positive control in analytical assays such as enzyme-linked immunospot (ELISpot), flow cytometry, and peptide-MHC multimer staining. Its well-characterized sequence and reproducible activity enable robust assay calibration, validation, and quality control, supporting the generation of reliable experimental data in immunological research workflows.

1. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII

2. An Isolated TCR αβ Restricted by HLA-A* 02: 01/CT37 Peptide Redirecting CD8+ T Cells to Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines

3. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists

4. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

5. Olfactory receptor based piezoelectric biosensors for detection of alcohols related to food safety applications